GS

Gauri Shankar

Active Director Director DIN 09762893
DIN 09762893 First appointment Oct 2022 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2022
Shareholding value •••• Premium profile

About Gauri Shankar

Data last updated:

Gauri Shankar is a Director at Terrace Pharmaceuticals Private Limited (since 2022). The company operates in Pharma. Terrace Pharmaceuticals Private Limited reported revenue of ₹40.75 Cr (FY 2024).

DIN 09762893
Primary Designation Director
Industry Pharma
First Appointment 12 Oct 2022
Oldest Company Age 20 yrs
Largest company Terrace Pharmaceuticals Private Limited · ₹40.75 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director12 Oct 20222005₹40.75 Cr (FY 2024)Active

Board colleagues of Gauri Shankar

Directorship timeline

Open interactive timeline →
Terrace Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Gauri Shankar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gauri Shankar

Gauri Shankar currently holds 1 directorship: Terrace Pharmaceuticals Private Limited (Director, since 12 Oct 2022, revenue ₹40.75 Cr (FY 2024)).

Gauri Shankar was first appointed on 12 Oct 2022 as Director at Terrace Pharmaceuticals Private Limited.

The current boards of Gauri Shankar's companies include Parveen Kumar (Terrace Pharmaceuticals Private Limited), Robin Chopra (Terrace Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available